Given that ANXA1 is an extremely specific tumor vasculature surface marker [2], and IF7-conjugated anti-cancer drugs have significant effects on subcutaneous and brain tumors [8, 9, 36], a drug conjugated to an ANXA1-binding peptide should eradicate tumors effectively at low dosage with few side effects. This evidence concerns the gene ANXA1 and cancer.